Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Patient-Reported Outcomes Support First-Line Pembrolizumab for NSCLC

Key clinical point: Patient-reported outcomes support pembrolizumab plus chemotherapy for first-line treatment of metastatic non–small cell lung cancer.

Major finding: At week 18, a higher percentage of patients in the pembrolizumab plus chemotherapy group reported improvements in health-related quality of life, compared with patients in the placebo plus chemotherapy group (36.2% . 27.7%).

Study details: An analysis of patient-reported outcomes in the phase 3 KEYNOTE-407 trial.

Disclosures: The study was funded by Merck. The investigators reported additional relationships with Novartis, Genentech, Pfizer, and others.

Citation:

Mazieres J et al. J Clin Oncol. 2019 Nov 21. doi: 10.1200/JCO.19.01348.